Pasireotide for the Medical Management of Feline Hypersomatotropism

por Scudder, C.J., Gostelow, R., Forcada, Y., Schmid, H.A., Church, D., Niessen, S.J.M.
Publicado 2015

Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism

por Gostelow, R., Scudder, C., Keyte, S., Forcada, Y., Fowkes, R.C., Schmid, H.A., Church, D.B., Niessen, S.J.M.
Publicado 2017

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

por Urbonas, V, Schadendorf, D, Zimmer, L, Danson, S, Marshall, E, Corrie, P, Wheater, M, Plummer, E, Mauch, C, Scudder, C, Goff, M, Love, S B, Mohammed, S B, Middleton, M R
Publicado 2019

Hypersomatotropism in 3 Cats without Concurrent Diabetes Mellitus

por Fletcher, J.M., Scudder, C.J., Kiupel, M., Pipe‐Martin, H.N., Kenny, P.J., Mantis, P., Fenn, J., Smith, K., Blair, R.V., Granger, L.A., Niessen, S.J.M.
Publicado 2016